Investment Rating - The report maintains a "Buy" rating for the company [7][8]. Core Insights - The company has benefited from the rise of domestic mid-tier brands and is strategically enhancing its global business operations [1][4]. - In H1 2025, the company achieved a revenue of 371 million yuan, representing a year-on-year growth of 39.3%, and a net profit attributable to shareholders of 17 million yuan, up 14.9% year-on-year [4][6]. - The company is focusing on high-quality product development and has established stable partnerships with various brands, which is expected to drive revenue growth [7]. Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 1.009 billion yuan, with a year-on-year growth rate of 45.2% [6]. - The net profit attributable to shareholders is forecasted to be 69 million yuan in 2025, with a significant growth rate of 52.6% [6]. - The company’s gross margin is projected to be 26.4% in 2025, with a gradual increase expected in subsequent years [6]. Business Segmentation - The skincare segment remains the core business, accounting for 89.5% of total revenue in H1 2025, with significant growth driven by new customer orders [7]. - The company has developed over 50 high-quality products and is actively expanding its market presence both domestically and internationally [7]. Market Positioning - The company is strategically positioned to leverage the growing demand for domestic brands and is enhancing its supply chain capabilities to support market expansion [7]. - The report highlights the company's focus on high-quality exhibitions to promote its global business, targeting key markets in Europe and North America [7].